Format

Send to

Choose Destination
J Pediatr Adolesc Gynecol. 2004 Feb;17(1):17-21.

Bone mineral density in adolescent females using depot medroxyprogesterone acetate.

Author information

1
Kaza Medical Group, 113 Neurology Way, Milford, DE 19963, USA. elaratorre@yahoo.com

Abstract

STUDY OBJECTIVE:

To examine bone mineral density (BMD) on a semi-annual basis among control subjects and adolescent females receiving depot medroxyprogesterone acetate (DMPA) injection or oral contraceptives.

DESIGN:

Non-randomized prospective study.

SETTING:

Teenage pregnancy prevention intervention clinic.

PARTICIPANTS:

Adolescent females who were new users of DMPA injection (N=58, age 12-21) or the oral contraceptive pill (N=71, age 11-19) and normal menstruating girls (N=19, age 15-18).

INTERVENTIONS:

Baseline and 6-monthly measures of lumbar vertebral BMD using dual-energy X-ray absorptiometry over a 2-year period.

MAIN OUTCOME MEASURES:

comparison of percent change on BMD over time between DMPA users, pill users, and normal menstruating girls.

RESULTS:

There was no difference on group characteristics at baseline except for the ethnicity between the controls and the DMPA group. There was a statistically significant decrease in BMD between DMPA users and controls at 6 months (-3.02% change, P=0.014) 12 months (-3.38% change, P=0.001) 18 months (-4.81% change, P<0.001) and 24 months (-6.81% change, P=0.010). There was no statistical difference between pill users and controls.

CONCLUSION:

There is a relationship between DMPA use and a decrease in BMD compared to normal menstruating controls that seems to persist up to 24 months.

PMID:
15010034
DOI:
10.1016/j.jpag.2003.11.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center